Acta Chim. Slov. 2005, 52, 187–199 187 Review Article Applications of Boronic Acids in Selective C-C and C-N Arylation of Purines J. Jacob Strouse, Marjan Ješelnik, and Jeffrey B. Arterburn* Department of Chemistry & Biochemistry MSC 3C, New Mexico State University, P.O. Box 30001, Las Cruces, NM 88003 U.SA. E-mail: jarterbu@nmsu.edu Received 17-08-2005 Abstract Substituted purine derivatives have broad biomedical value as therapeutics, and have attracted great interest as molecular tools and probes for investigating biological systems. The modification of purines with aryl or heteroaryl substituents dramatically alters conformational preferences, the steric profile, and hydrogen-bonding capacity. The development of new methods for metal-mediated coupling with aryl or heteroaryl halide substrates has greatly expanded the range of synthetically accessible arylpurine derivatives. Arylboronic acids have proven to be extremely effective reagents for the synthesis of arylpurine compounds. Arylboronic acids are stable, versatile, and readily available reagents for metal-mediated C-C and C-N coupling reactions. Coupling reactions resulting in C-C bond formation are catalyzed by palladium and nickel catalysts at positions C2, C6, and C8. Copper mediated N-arylation occurs at positions N1, N2’, N7, and N9. These methods are also applicable using solid supported purine substrates. Successful coupling involves careful optimization of catalyst, ligand, base, solvent, and reaction temperature. These methods provide convenient access to structurally unique arylpurine derivatives with applications in drug discovery and chemical biology. Key words: C-C coupling, C-N coupling, Aryl-Purine Derivatives Contents INTRODUCTION ..................................................................................................187 CATALYTIC C-C COUPLING C6-arylation ......................................................................................................189 C2-arylation ......................................................................................................192 C8-arylation ......................................................................................................194 Solid supported purine substrates..................................................................195 COPPER MEDIATED C-N COUPLING N9-arylation ......................................................................................................196 N2’-arylation .....................................................................................................196 N^a^lation ......................................................................................................196 BIOACTIVE ARYL-PURINE DERIVATIVES ..............................................197 CONCLUSIONS AND PERSPECTIVES..............................................................198 REFERENCES .......................................................................................................198 Introduction Purines are one of the most important classes of heterocyclic compounds in biology, fulfilling functional roles as nucleic acids, coenzymes, and constituents in metabolic processes, energy storage, and celi signaling. A wide variety of substituted purine derivatives have been isolated from natural sources.1 The purine ring system is susceptible to substitution through both nucleophilic SNAr and alkylation with electrophilic reagents. The introduction of substituents can affect the sterics, hydrogen-bonding, and hydrophobicity that results in altered interactions with nucleic acids and proteins. It is well known that even minor structural modifications of nucleosides can greatly affect their biological activity and metabolism. Substituted purine derivatives have broad biomedical value as therapeutics, and have attracted great interest as molecular tools and probes for investigating biological systems.2 The modification of purines with aryl or heteroaryl substituents dramatically alters conformational preferences, the steric profile, and hydrogen-bonding capacity. The alkylation of purines with polycyclic aromatic hydrocarbons is related to the carcinogenic Strouse et al. Selective C-C and C-N Arylation of Purines 188 Acta Chim. Slov. 2005, 52, 187–199 and other genotoxic effects associated with these compounds.3 Mutagenic intrastrand DNA cross-links are formed from dietary and environmental exposure to oxides of nitrogen.4 Aryl purine derivatives exhibit biomedically relevant activity including antiviral, antibacterial, anticancer, and antihypertensive properties. Aryl purine derivatives can be prepared by displacement of electrophilic halogenated purines with aryl nucleophiles, or through the reaction of nucleophilic purines with activated, electron deficient arylating agents. While direct substitution has been successful for the synthesis of many derivatives, the electronic requirements and forcing reaction conditions limit the scope of this approach. The development of new methods for metal-mediated coupling with aryl or heteroaryl halide substrates has greath/ expanded the range of synthetically accessible aryl purine derivatives. These methods have been the subject of several recent reviews.5 The inherent capacity of heteroatoms as ligands constitutes one of the greatest challenges to metal-mediated coupling reactions of heterocyclic compounds. The N1, N2’, N3, N6’, O6 and N7-positions of purines are possible coordination sites with mono and bidentate binding modes. The application of metal-mediated arylation with purine substrates requires careful optimization of catalyst, ligand, base, solvent, and reaction temperature. Frequently, individualized experimental conditions are required for a specific reactive pair of purine substrate and arylating reagent. Boronic acids exhibit desirable characteristics that are advantageous when compared to other organometallic and organometalloid reagents. Boronic acids can be synthesized from a variety of precursors and are typically stable and easily stored. A wide range of substituted aryl and heteroarylboronic acids are commercially available, including a variety of functional groups, different ring sizes and conjugated systems. This diversity in boronic acid substrates facilitates mechanistic investigations and is particularly valuable for structure activity relationships in medicinal chemistry. Boronic acids and boron-containing byproducts are typically non-toxic and easily removed from reaction mixtures, even on large scale. Arylboronic acids have proven to be extremely effective reagents for the synthesis of biaryl compounds using the palladium catalyzed Suzuki-Miyaura coupling reaction.6 Suzuki reactions can be performed using a variety of organic solvents including aqueous systems. The success achieved in palladium-catalyzed cross coupling chemistry has been paralleled by new developments in the classical copper mediated Ullmann Reaction.7 The Chan-Evans-Lam copper(II)-catalyzed C-N and C-O coupling procedure with boronic acids has been extended to amines, analines, amides, imides, ureas, carbamates, sulfonamides, and phenols.8 Recently, coupling procedures involving boronic acids have been extended to purine substrates. This review focuses on the metal-mediated C-C and C-N arylation of purine derivatives with arylboronic acids. This approach provides access to a wide variety of mono-, di-, and tri-substituted aryl and heteroarylpurines as summarized graphically in Scheme 1. R-B(OH)2 ~NH OH Scheme 1 Biographical Sketches /. Jacob Strouse (left), born in Las Cruces, New Mexico (USA) in 1976, completed his undergraduate degrees in 2000 from New Mexico State University. He continued under the mentorship of Jeffrey B. Arterburn at New Mexico State University and is currently a senior chemistry Ph.D. candidate with focus on the copper mediated synthesis of arylnucleoside derivatives. Marjan Ješelnik (center), born in Ljubljana (Slovenia) in 1970, completed his Ph.D. in organic chemistrv in 2000 at the Universitv of Ljubjana. He conducted postdoctoral research in metal-mediated arvlation of heterocycles under supervision of Prof. Jeffrev B. Arterburn. Jeffrey B. Arterburn (right), born in Denver, Colorado (USA) in 1962, completed his Ph.D. in organic chemistrv in 1990 at the Universitv of Arizona, Tucson under the direction of EA. Mash. He conducted postdoctoral research in organometallic chemistrv at the ETH Zurich with Prof. D. Seebach, and the Universitv of Washington with Prof. J. M. Maver. He has been a facultv member in the Department of Chemistrv & Biochemistrv at New Mexico State Universitv since 1992, where he holds the rank of Professor, and serves as the Director of the New Mexico IDeA Network of Biomedical Research Program. Strouse et al. Selective C-C and C-N Arylation of Purines Acta Chim. Slov. 2005, 52, 187–199 189 Catalytic C-C Coupling C6-arylation The first example of the Suzuki-Miyaura cross coupling reaction using halogenated purine derivatives was reported by Havelková in 1999.9 Several different catalyst precursors, bases, solvents, and reaction conditions were evaluated for C6-arylation of the 9-benzyl 6-chloropurine substrate. Two optimized procedures employing Pd(PPh3)4 as catalyst were developed; anhydrous conditions using K2C03 and toluene, or aqueous K2C03 and dimethoxyethane (DME). Both of these procedures were effective for C6-arylation with phenylboronic acid, providing the 6-phenylpurine product in 95% yield (Scheme 2). Bn c6 N Bn Anhydrous Conditions 2.5 mol% Pd(PPh3)^, K2C03, MePh, 100°C Aqueous Conditions 2.5 mol% Pd(PPh3)„, aq. K2C03, DME, 85 °C H aOMe 4 -\ ^" "N02 Anhyd. 95% 62% 19% Aq. 95% 39% Scheme 2 66% !5?% coupling was observed using pentafluorophenylboronic acid under either of these reaction conditions. The coupling reaction also proceeded in aqueous DMF but at reduced rates. Butylboronic acid gave low yields of coupled product using the anhydrous conditions. These procedures have been applied in a series of related synthetic investigations. The tri-0-acetyl protected ribonucleosides of 6-chloropurine and 2-amino-6-chloropurine were converted to the 6-phenyl derivatives in good yields using the anhydrous conditions (Scheme 3). The acetyl protecting groups were stable under these conditions, and no arylation of the N2’-amine was observed. Cl AcO OMe X = Br X = Cl 91% 93% 69% 83% 59% 84% '\^ "N02 [ S 49% 84% K^ o *c 58% 74% Scheme 5 Reaction times were significantly shorter using these conditions than the anhydrous conditions involving Pd(PPh3)4/anhydrous K2C03 (lh vs. 8h respectively) and product yields were comparable. The bis-cyclohexyl ligand was much more effective than the closeh/ related t-butyl analog. This investigation directh/ compared the reactivity of 6-C1 and 6-bromopurine substrates. A similar electronic preference to that previously observed using the anhydrous conditions for electroneutral and electron rich arylboronic acids was reflected in the product yields obtained from the 6-bromopurine substrate. Interestingh/, the 6-chloropurine substrate gave good product yields using both electron rich and electron poor arylboronic acids. The catalytic procedure for the 6-chloro substrate was modified slighth/ by pre-mixing the Pd/ligand, however, no advantage for pre-mixing was observed for the 6-bromopurine. Chlorination of guanosine provides a convenient method for preparation of the 2-amino-6-chloropurine ribonucleoside, however, the analogous conversion of the labile 2’-deoxyguanosine analog proceeds in low yields. Aryl iodides are typically much more reactive than bromides and chlorides in palladium catalyzed reactions. A series of iodopurine substrates have been investigated (Scheme 6). The reaction of the 9-benzyl-6-iodopurine with phenylboronic acid proceeded rapidly under the anhydrous conditions, but the resulting reaction mixture was not as clean as that obtained from the 6-chloro substrate.9 Liu et al. recenth/ reported the facile conversion of toluoyl-protected 6-chloro ribonucleosides to the 6-iodopurine derivatives using a low temperature SNAr reaction.16 The 6-iodopurine gave better yields of 6-p-methoxyphenyl product than the corresponding chloro-derivative under the anhydrous conditions. Selective C6-arylation was observed using the acetyl protected 8-bromo-6-iodopurine ribonucleoside under anhydrous conditions.17 Subsequent nucleophilic displacement of the 8-bromo group in the coupled product was facile. M" TolO N'VN^ \^ Havelkova1999 TolO OTol N Bn < k >: MesO OMes Yield 82% OMe 73% Liu et al. have described nickel-carbene catalyzed cross coupling reactions of 6-azol-purine nucleoside substrates (Scheme 12). Derivatives such as the 6-(imidazol-l-yl)purine and 6-(l,2,4-triazol-4-yl)purine are readily prepared from the corresponding nucleosides. Cesium fluoride was the most effective base for coupling the triazole derivatives, while potassium phosphate was effective for the imidazole substrates. Small amounts of Oe-phenyl byproducts were observed under these conditions.21 N-N O N N- ¦N AcO AcO N^N Ni(COD)2, L2, G R-B(OH)2 CsF, THF, 60°C AcO AcO R Yteld rt '^r s" •\J J 78% 1 ^ ^OMe ^ J 85% "¦>, X ..'<-J 75% Scheme 12 Scheme 11 C2-arylation A variety of N9-substituted (benzyl, tetrahydropyranyl, tribenzyl-ribose, ditolyl-2’-deoxy-ribose) 2-chloro-6-methylpurine derivatives have been shown to react efficiently at C2 under the anhydrous conditions (Scheme 13).22 Ding et al. showed the 6,9-disubstituted 2-chloropurine substrate coupled in high yield with tris(dibenzylideneacetone)dipalladium (Pd2(dba)3) and the carbene ligand l,3-bis(2,4,6-trimethylphenyl)imida zolin-2-ylidene L3. The choice of base was significant and Cs2C03 provided the best results. Lower yields were obtained using ort/zo-substituted or electron deficient arylboronic acids (Scheme 14).n The anhydrous conditions (Pd(PPh3)4, K2C03) are also effective with this substrate.23 Strouse et al. Selective C-C and C-N Arylation of Purines Acta Chim. Slov. 2005, 52, 187–199 193 9H> Pd(Pph3)4 ?H* PhMe, 90°C * °v\' a BzO BzO OBz Tol(X ^ Yield 98% 96% 73% 89% TolO Scheme 13 Wan et al. synthesized a novel set of trisubstituted C2-arylpurine derivatives utilizing the differential reactivitv of halogens at C2 and C6 as illustrated in Scheme 15. Selective SNAr substitution with sodium methvlsulfide occurred at the more reactive 6-position of 2,6-dichloro-9-methylpurine. Cross-coupling of the resulting 2-chloropurine substrate with aqueous NaHC03, dioxane conditions afforded the C2-aryl product. Subsequent oxidation of the 6-sulfanyl group with Oxone® gave the sulfonyl compound in 43% over two steps. The activated 6-sulfonyl derivative then undergoes substitution at C6 with 2,6-difluoroaniline in high yield.24 Selective C2-arylation has been accomplished using 6-chloro-2-iodopurine substrates as shown in OMe . Pd2(dba)3, L3 | R-B(OH)2 OMe CsC03 dioxane. 80°C L3 = 1,3-bis(2,4,6-trimethylphenyl) imidazolin-2-ylidene R Yield 93% 94% 96% Scheme 14 Scheme 16. Using 1 eq. PhB(OH)2 under anhydrous conditions with 9-benzyl 6-chloro-2-iodopurine gave the 2-phenyl product in excellent yield.10 The reaction was noted to be slower than the C6-arylation of 9-benzyl-2,6-dichloropurine. These same conditions were used for the acetyl-protected ribonucleoside derivative.25 Diarylation occurs in the presence of excess boronic acid. Selective nucleophilic displacement occurs at the more reactive C6 position of 6-chloro-2-iodopurine derivatives, and the resulting 2-iodopurine substrates have been shown to undergo efficient cross coupling at C2.24 I NaSMe, DMSO SMe 1 N X. F^r^B(OH)2 * (Ti N Cl Pd(PPh3)4, NaHCOg, dioxane/water 43% (2 steps) Scheme 15 Strouse et al. Selective C-C and C-N Arylation of Purines 194 Acta Chim. Slov. 2005, 52, 187–199 Cl I Pd(PPh3)4, N_^N Ph-B(OH)2 * X x~ C\ N" I R K2C03, PhMe w R Yield Bn 81% triacetylnbose 76% Scheme 16 Lakshman et al. investigated cross-coupling reactions with the protected Oe-benzyl-2-bromopurine substrate derived from 2’-deoxyguanosine as shown in Scheme 17. The catalyst and reaction conditions previously optimized for C6-arylation were also effective for C2-arylation. The efficient two-step process for synthesizing 2-aryl-2’-deoxyinosine derivatives was completed by subsequent deprotection.15 TBSO V^J OBn N Br TBSO Pd(OAc)2, L1, R-B(OH)2 K3PO4 dioxane; 100°C 2. H2, Pd/C, THF/MeOH TBSO v^ OBn TBSO R -V \- -v OMe Yield (2 step) 73% 58% 56% Scheme 17 C?-arylation Cross-coupling with 6-amino-8-bromopurine substrates has been investigated as shown in Scheme 18. The Pd(PPh3)4 catalyzed coupling reactions of 9-benzyl protected 6-amino-8-bromopurine with phenylboronic acid were successful using both anhydrous conditions and the aqueous K2C03 system. The aqueous conditions were more effective with electron deficient boronic acids.10 This approach was also used to prepare C8-phenyl-2’3’-dideoxyadenosine in good yield.26 The unprotected ribonucleoside 8-bromoadenosine was arylated in good yield using a series of boronic acids under these conditions.27 Aqueous conditions using water-soluble sulfonated phosphine ligands have also been investigated for the coupling of 8-bromoadenosine. Catalvtic palladium acetate, tris(3-sulfonatophenyl)ph osphine, Na2C03, and H20-CH3CN at 80 °C afforded C8-aryl products in good yields.28 The 2’-deoxyribose derivative was also arylated effectively under these conditions. The reaction could be performed at room temperature using the more sterically hindered o,p-dimethyl substituted (3-sulfonatophenyl)phosphine ligand. This method has been used to prepare 8-aryl-2’-deoxyguanosine derivatives.29 NH2 » ,OMe vU 86% 61 %a f^l AJ- ""N02 97% 51%3 > O O H ij Kim1999 Bn Gundersen 2002 HO OH Scheme 26 The protein kinase family offers great challenge and opportunity for drug discovery targeting diseases such as cancer, autoimmune diseases, inflammation, allergic reactions, neurological disorders, and hormone-related diseases. Kinases regulate many different signal transduction pathways, celi differentiation, and celi proliferation processes. Ali of the identified kinases bind the cofactor adenosine triphosphate in a similar way; however structural diversity exists between members of the kinase family in regions unoccupied by ATP. Phenylation of purine substrates provides novel structures to probe this diversity and enhance selective interactions with hydrophobic regions.40 The C8-arylpurine derivative developed by Kim et al. binds human A2B receptor with K; = 19 nM and exhibits selectivity factors of 160/100/35 for human Aj/A2A and A3 receptors respectiveh/.41 Wan et al. have designed a novel series of 2,6,9-trisubstituted purine derivatives as inhibitors of p38a MAP kinase. Direct evidence for the selective Strouse et al. Selective C-C and C-N Arylation of Purines 198 Acta Chim. Slov. 2005, 52, 187–199 interaction of the C2-fluorophenyl group with a hydrophobic pocket in p38a kinase was obtained by X-ray crystallography.24 Hocek et al. have identified 6-phenylpurine ribonucleosides that inhibit celi growth in vitro against mouse leukemia L1210 cells, human cervix carcinoma HeLa S3 cells, and human T-lymphoblastoid CCRF-CEM cells. The related 2-amino-6-aryl derivatives and aglycosides were inactive.42 9-benzyl-2-chloro-6-(2-furyl)purine exhibited antibacterial activity against Mycobacterium tuberculosis H37-Rv and was active against several drug-resistant strains.43 Conclusions and Perspectives The metal-mediated C-C and C-N coupling reaction of purines with boronic acids has been shown to be a powerful synthetic method for introducing aryl or heteroaryl substituents. Several different palladium catalyst-ligand combinations have been used for C-C coupling at the C6 position. This reactivity has been demonstrated using fluoro-, chloro-, bromo-, iodo-, sulfanyl, sulfonyl, sulfonyloxy- and azole-substrates. The ease of obtaining the activated purine substrates is an important factor when selecting appropriate coupling conditions, particularly for nucleoside derivatives. Important advances in the general applicability of this methodology have been made, however, careful optimization of catalyst, ligand, base, solvent, and reaction temperature is frequently necessary. Palladium catalysts have also enabled C-C coupling at positions C2, and C8. Copper mediated N-arylation occurs at positions N1, N2’, N7, and N9. Examples of combinatorial approaches employing coupling reactions with solid supported purine substrates have also been reported. These methods provide convenient access to structurally unique arylpurine derivatives with applications in drug discovery and chemical biology. Continuing advances in this field can be expected to result through improved mechanistic understanding and the development of new catalysts and ligands. Acknowledgements The authors research program was supported by R21 AI053304 from NIAID. J.J.S. was supported by NIH/RISE GM61222. References 1. H. Rosenmever, Chem. Biodiversity 2004, 1, 361-401. 2. (a) G. E. Wright,^4cto. Biochim. Pol. 1996, 43, 115-124. (b) M. Williams, M. F. Jarvis, Biochem. Pharmacol. 2000, 59, 1173-1185. (c) A. Bishop, O. Buzko, S. Heveck-Dumas, I. Jimg, B. Kravbill, Y. Liu, K Shah, S. Ulrich, L. Witucki, F. Yang, C. Zhang, K M. Shokat, Annu. Rev. Biophys. Biomol. Struc. 2000, 29, 577-606. (d) J. T. Daviš, Angew. Chem. Int. Ed. 2004, 43, 668-698. 3. R. G. Harvev, N. E. Geacintov,^4cc. Chem. Res. 1988, 21, 66-73. 4. E. A. Hanvood, S. T. Sigurdsson, N. B. F. Edfeldt, B. R. Reid, P. B. Hopkins, /. Am. Chem. Soc. 1999, 121, 5081-5082. 5. (a) M. K. Lakshman, /. Organomet. Chem. 2002, 653, 234-251. (b) M. Hocek, Eur. J. Org. Chem. 2003, 2, 245-254. (c) L. A. Agrofoglio, I. Gillaizeau, Y. Saito, Chem. Rev. 2003, 103, 1875-1916. (d) M. K Lakshman, Curr. Org. Synth. 2005, 2, 83-112. 6. (a) N. Mivaura, A. Suzuki, Chem. Rev. 1995, 95, 2457-2483. (b) S. Kotha, K. Lahiri, D. Kashinath, Tetrahedron 2002, 58, 9633-9695. 7. S. V Ley, A. W. T\\om&s, Angew. Chem. Int. Ed. 2003, 42, 5400-5449. 8. (a) D. M. T. Chan, K L. Monaco, R. Wang, M. P. Winters, Tetrahedron Lett. 1998, 39, 2933-2936. (b) D. A. Evans, J. L. Katz, T. R. West, Tetrahedron Lett. 1998, 39, 2937-2940. (c) P. Y. S. Lam, C. G. Clark, S. Saubern, J. Adams, M. P. Winters, D. M. T. Chan, A. Combs, Tetrahedron Lett. 1998, 39, 2941-2944. 9. M. Havelková, M. Hocek, M. Česnek, D. Dvorak, Synlett 1999, 1145-1147. 10. M. Havelková, D. Dvoák, M. Hocek, Synthesis, 2001, 1704-1710. 11. S. Ding, N. S. Gray, Q. Ding, P. G. Schultz, Tetrahedron Lett. 2001, 42, 8751-8755. 12. M. Hocek, A. Holý, I. Votruba, H. Dvofaková, Collect. Czech. Chem. Commun., 2001, 66, 483-499. 13. (a) M. Hocek, D. Hocková, H. Dvofaková, Synthesis 2004, 889-894. (b) M. Česnek, M. Hocek, A. Holý, Collect. Czech. Chem. Commun. 2000, 65, 1357-1373. (c) M. Hocek, A. Holý, I. Votruba, H. Dvofaková, Collect. Czech. Chem. Commun., 2000, 65, 1683-1697. (d) F. Fernández, X. Garcfa-Mera, M. Morales, J. E. Rodrfguez-Borges, E. De Clercq, Synthesis 2002, 1084-1090. 14. M. Havelková, D. Dvofak, M. Hocek, Tetrahedron 2002, 58, 7431-7435. 15. M. K Lakshman, J. H. Hilmer, J. Q. Martin, J. C. Keeler, Y. Q. V Dinh, F. N. Ngassa, L. M. Russon,/. Am. Chem. Soc. 2001, 123, 7779-7787. 16. J. Liu, M. J. Robins, Org. Lett. 2004, 6, 3421-3423. 17. M. Hocek, D. Hocková, J. Štambaský, Collect. Czech. Chem. Commun. 2003, 68, 837-848. 18. M. K. Lakshman, P. F. Thomson, M. A. Nuqui, J. H. Hilmer, N. Sevova, B. Boggess, Org. Lett. 2002, 4, 1479-1482. 19. P. Gunda, L. M. Russon, M. K. Lakshman,^4wgevu Chem. Int. Ed. 2004, 43, 6372-6377. 20. J. Lui, M. J. Robins, Org. Lett. 2005, 7, 1149-1151. Strouse et al. Selective C-C and C-N Arylation of Purines Acta Chim. Slov. 2005, 52, 187–199 199 21. J. Liu, Z. Janeba, M. J. Robins, Org. Lett. 2004, 6, 2917-2919. 22. M. Hocek, H. Dvofaková, /. Org. Chem. 2003, 68, 5773-5776. 23. M. Hocek, I. Votruba, H. Dvofaková, Tetrahedron 2003, 59, 607-611. 24. Z. Wan, J. C. Boehm, M. J. Bower, S. Kassis, J. C. Lee, B. Zhao, J. L. Adams, Bioorg. Med. Chem. Lett. 2003, 13, 1191-1194. 25. M. Hocek, A. Holý, H. Dvofaková, Collect. Czech. Chem. Commun., 2002, 67, 325-335. 26. K. S. Gudmimdsson, S. M. Daluge, L. D. Condreav, L. C. Johnson, Nucleosides, Nucleotides Nucleic Acid 2002, 21, 891-901. 27. N. Kohvama, T. Katashima, Y. Yamamoto, Synthesis, 2004, 2799-2804. 28. E. C. Western, J. R. Daft, E. M. Johnson, II, P. M. Gannett, K. H. Shaughnessv, /. Org. Chem. 2003, 68, 6767-6774. 29. (a) P. M. Gannett, S. Heavner, J. R. Draft, K. H. Shaughnessv, J. D. Epperson, N. L. Greenbaum, Chem. Res. Toxicol. 2003, 16, 1385-1394. (b) V Gubala, J. E. Betancourt, J. M. Rivera, Org. Lett. 2004, 6, 4735-4738. 30. (a) N. Amann, H. Wagenknecht, Synlett 2002, 687-691. (b) E. Maver, L. Vališ, R. Huber, N. Amann, H. Wagenknecht, Synthesis 2003, 2335-2340. 31. K. Vollman, C. E. Müller, Heterocycles 2002, 57, 871-879. 32. (a) C. Riva-Toniolo, S. Müller, J. Schaub, W. K. D. Brili, Mol. Diversity 2003, 6, 43-53. (b) J. T. Bork, J. W. Lee, Y. Chang, QSAR Comb. Sci. 2004, 23, 245-260. 33. V. Brun, M. Legraverend, D. S. Grierson, Tetrahedron 2002, 58, 7911-7923. 34. S. Ding, N. S. Gray, X. Wu, Q. Ding, P. G. Schultz,/. Am. Chem. Soc. 2002, 124, 1594-1596. 35. W. K D. Brili, C. Riva-Loniolo, S. Müller, Synlett 2001, 1097-1100. 36. W. K. D. Brili, C. Riva-Loniolo, Tetrahedron Lett. 2001, 42, 6515-6518. 37. A. K. Bakkestuen, L. Gundersen, Tetrahedron Lett. 2003, 44, 3359-3362. 38. R. A. Joshi, P. S. Patil, M. Muthukrishnan, C. V Ramana, M. K Gujar, Tetrahedron Lett. 2004, 45, 195-197. 39. J. J. Strouse, M. Ješelnik, F. Lapaha, C. B. Jonsson, W. B. Parker, J. B. Arterburn, Tetrahedron Lett. 2005, 46, 5699-5702. 40. (a) B. C. Bookser, M. C. Matelich, K Ollis, B. G. Ugarkar, /. Med. Chem. 2005, 48, 3389-3399. (b) S. A. Laufer, D. M. Domever, L. R. F. Scior, W. Albrecht, D. R. J. Hauser, /. Med. Chem. 2005, 48, 710-722. 41. Y. Kim, Y Karton, X. Ji, N. Melman, J. Linden, K. A. Jacobson, Drug Dev. Res. 1999, 47, 178-188. 42. M. Hocek, A. Holý, I. Votruba, H. Dvofakova, /. Med. Chem. 2000, 43, 1817-1825. 43. L. Gundersen, J. Nissen-Meyer, B. Spilsberg, /. Med. Chem. 2002, 45, 1383-1386. Povzetek Substituirani derivati purina imajo velik biomedicinski pomen kot terapevtiki in so pritegnili veliko pozornost kot molekulska orodja in testne spojine za raziskave bioloških sistemov. Modifikacije purinov z arilnimi ali heteroarilnimi substituenti dramatično spremenijo konformacijske preference in sposobnost tvorbe vodikovih vezi. Razvoj novih metod za spajanje purinov z aril ali heteroaril halogenidi s pomočjo kovinskih katalizatorjev je zelo povečal možnosti sinteze arilpurinskih derivatov. Arilboronske kisline so se izkazale kot zelo učinkoviti reagenti za sintezo arilpurinskih spojin, s tvorbo bodisi C–C ali C–N vezi. Paladij in nikelj katalizirata nastanek vezi C–C na položajih C2, C6 ali C8, baker pa nastanek vezi C–N na položajih N1, N2, N7 in N9. Metoda je uporabna tudi za purine, vezane na trdne nosilce. Za uspešnost reakcije je bistvena optimizacija katalizatorja, liganda, baze, topila in temperature reakcije. Te reakcije predstavljajo pripravno metodo za sintezo arilpurinskih derivatov za biološke in medicinske študije. Strouse et al. Selective C-C and C-N Arylation of Purines